Britta Weigelt
#133,286
Most Influential Person Now
Researcher
Britta Weigelt's AcademicInfluence.com Rankings
Britta Weigeltcomputer-science Degrees
Computer Science
#5974
World Rank
#6301
Historical Rank
Machine Learning
#1787
World Rank
#1810
Historical Rank
Artificial Intelligence
#2035
World Rank
#2069
Historical Rank
Database
#3096
World Rank
#3226
Historical Rank
Download Badge
Computer Science
Britta Weigelt's Degrees
- Masters Computer Science Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Britta Weigelt Influential?
(Suggest an Edit or Addition)Britta Weigelt's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Breast cancer metastasis: markers and models (2005) (2145)
- Concordance among gene-expression-based predictors for breast cancer. (2006) (1370)
- A large-scale RNAi screen in human cells identifies new components of the p53 pathway (2004) (1123)
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015) (844)
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011) (629)
- Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007) (598)
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma (2015) (523)
- Classification of endometrial carcinoma: more than two types. (2014) (467)
- The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade (2010) (457)
- Gene expression profiles of primary breast tumors maintained in distant metastases (2003) (454)
- Histological types of breast cancer: How special are they? (2010) (429)
- Histological and molecular types of breast cancer: is there a unifying taxonomy? (2009) (419)
- Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. (2005) (367)
- Breast cancer molecular profiling with single sample predictors: a retrospective analysis. (2010) (362)
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. (2018) (348)
- HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment (2010) (306)
- Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. (2008) (298)
- The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. (2014) (292)
- Breast cancer intra-tumor heterogeneity (2014) (258)
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (229)
- The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type (2010) (225)
- Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. (2017) (222)
- Progression from ductal carcinoma in situ to invasive breast cancer: Revisited (2013) (220)
- Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis (2009) (212)
- Refinement of breast cancer classification by molecular characterization of histological special types (2008) (198)
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs (2011) (197)
- Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas (2010) (183)
- Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands (2014) (178)
- An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers (2010) (173)
- Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations (2015) (171)
- Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations (2011) (170)
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies (2012) (163)
- SF3B1 mutations constitute a novel therapeutic target in breast cancer (2014) (161)
- The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. (2010) (157)
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (156)
- Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (156)
- Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection (2012) (154)
- The genetic landscape of endometrial clear cell carcinomas (2017) (150)
- Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type (2010) (143)
- Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. (2015) (142)
- In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer (2015) (138)
- Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers (2012) (137)
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement (2011) (136)
- Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction (2011) (135)
- Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) (2010) (128)
- Genomic landscape of adenoid cystic carcinoma of the breast (2015) (128)
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer (2011) (124)
- Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (123)
- Challenges translating breast cancer gene signatures into the clinic (2012) (122)
- PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (119)
- The Genomic Landscape of Male Breast Cancers (2016) (118)
- Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants (2016) (117)
- Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry (2013) (117)
- Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (110)
- The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas (2017) (109)
- Going with the Flow: From Circulating Tumor Cells to DNA (2013) (107)
- Detection of circulating breast tumor cells by differential expression of marker genes. (2002) (106)
- Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type (2009) (106)
- Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples (2017) (103)
- Road map to metastasis (2003) (103)
- The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. (2017) (101)
- Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients (2003) (100)
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (97)
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast (2014) (96)
- Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. (2019) (96)
- Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry (2010) (92)
- No common denominator for breast cancer lymph node metastasis (2005) (92)
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients (2021) (91)
- Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression (2016) (90)
- Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions. (2014) (87)
- Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. (2017) (87)
- Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. (2015) (86)
- Molecular Profiling: Moving Away from Tumor Philately (2010) (86)
- Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers (2004) (84)
- Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer (2018) (84)
- The value of cell‐free DNA for molecular pathology (2018) (82)
- Diverse alterations associated with resistance to KRAS(G12C) inhibition (2021) (82)
- IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. (2016) (81)
- Immunophenotypic and genomic characterization of papillary carcinomas of the breast (2012) (81)
- A Survey of DICER1 Hotspot Mutations in Ovarian and Testicular Sex Cord-Stromal Tumors (2015) (80)
- Uterine adenosarcomas are mesenchymal neoplasms (2016) (79)
- Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer (2012) (79)
- HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer (2017) (79)
- Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases (2017) (78)
- Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy (2020) (78)
- Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology (2016) (78)
- Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas (2004) (77)
- MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast (2015) (76)
- Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein (2016) (75)
- Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (75)
- The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. (2018) (74)
- FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer (2019) (74)
- TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers (2016) (73)
- Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers (2012) (72)
- Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity (2018) (72)
- Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival (2014) (71)
- A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome (2017) (70)
- Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2020) (70)
- A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks (2010) (70)
- Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival (2015) (69)
- Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016) (66)
- Compromised BRCA1-PALB2 interaction is associated with breast cancer risk (2017) (66)
- A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
- Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (65)
- Metaplastic breast carcinoma: more than a special type (2014) (64)
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer (2018) (63)
- Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. (2019) (61)
- The Genomic Landscape of Mucinous Breast Cancer. (2019) (60)
- Genomic profiling of histological special types of breast cancer (2013) (59)
- MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene (2018) (58)
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (57)
- Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2018) (55)
- The genetic landscape of breast carcinomas with neuroendocrine differentiation (2017) (52)
- Molecular targets and targeted therapeutics in endometrial cancer (2012) (51)
- Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (50)
- The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study (2015) (49)
- Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. (2018) (48)
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2018) (47)
- Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis (2012) (46)
- Genetic Analysis of Microglandular Adenosis and Acinic Cell Carcinomas of the Breast Provides Evidence for the Existence of a Low-grade Triple-Negative Breast Neoplasia Family (2016) (46)
- Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (45)
- Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation (2009) (45)
- PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma (2014) (44)
- Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. (2015) (43)
- Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways (2017) (43)
- Variations in stromal signatures in breast and colorectal cancer metastases (2010) (43)
- Microglandular adenosis associated with triple‐negative breast cancer is a neoplastic lesion of triple‐negative phenotype harbouring TP53 somatic mutations (2016) (43)
- Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast (2014) (43)
- Molecular profiling and molecular classification of endometrioid ovarian carcinomas. (2019) (42)
- Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort (2018) (42)
- Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer (2017) (42)
- Leiomyoma With Bizarre Nuclei: A Morphological, Immunohistochemical and Molecular Analysis of 31 Cases (2017) (41)
- Mammosphere‐derived gene set predicts outcome in patients with ER‐positive breast cancer (2009) (40)
- Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing (2014) (39)
- Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. (2016) (38)
- Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships (2016) (38)
- Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential (2019) (37)
- Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype‐matched ductal and lobular carcinomas (2010) (37)
- Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. (2018) (37)
- Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations (2013) (35)
- Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma (2018) (34)
- Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (34)
- Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. (2016) (34)
- A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
- Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer (2019) (33)
- Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases (2021) (32)
- Contralateral breast cancers: Independent cancers or metastases? (2018) (32)
- Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases (2018) (32)
- The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility (2016) (31)
- Are acinic cell carcinomas of the breast and salivary glands distinct diseases? (2015) (30)
- Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (30)
- Activating mutations in HER2: neu opportunities and neu challenges. (2013) (28)
- Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. (2020) (27)
- Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor (2016) (27)
- Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis (2017) (27)
- The molecular genetic make-up of male breast cancer. (2019) (27)
- Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary (2020) (27)
- Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. (2019) (26)
- Endometrial Carcinomas with a “Serous” Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations (2020) (25)
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
- Epistatic interactions and drug response (2014) (24)
- Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma (2020) (24)
- Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
- Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas (2021) (23)
- Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild‐type classic polymorphous low‐grade adenocarcinomas of the salivary gland (2016) (23)
- Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. (2012) (23)
- Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile (2016) (23)
- Somatic mutations in leukocytes infiltrating primary breast cancers (2015) (23)
- Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers (2019) (22)
- Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing (2016) (22)
- Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (22)
- Immunohistochemical Analysis of IDH2 R172 Hotspot Mutations in Breast Papillary Neoplasms: Applications in the Diagnosis of Tall Cell Carcinoma with Reverse Polarity (2019) (22)
- Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. (2019) (21)
- Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation (2020) (21)
- DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes (2016) (20)
- Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (20)
- Exploring Collagen Parameters in Pure Special Types of Invasive Breast Cancer (2019) (20)
- Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers (2020) (20)
- V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer. (2019) (20)
- PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid (2019) (20)
- Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis‐generating study (2017) (20)
- Massively Parallel Sequencing Analysis of 68 Gastric-Type Cervical Adenocarcinomas Reveals Mutations in Cell Cycle-Related Genes and Potentially Targetable Mutations (2020) (20)
- Absence of microsatellite instability in mucinous carcinomas of the breast. (2010) (20)
- Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma (2020) (19)
- High-Grade Transformation of Low-Grade Endometrial Stromal Sarcomas Lacking YWHAE and BCOR Genetic Abnormalities (2020) (19)
- DNA Mismatch Repair–deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas (2020) (19)
- Problematic breast tumors reassessed in light of novel molecular data (2020) (19)
- Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. (2015) (18)
- Histologic Spectrum of Polymorphous Adenocarcinoma of the Salivary Gland Harbor Genetic Alterations Affecting PRKD Genes (2019) (18)
- Microglandular adenosis: a non-obligate precursor of triple-negative breast cancer? (2013) (18)
- BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. (2020) (17)
- The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma (2018) (17)
- Hard Wired Genotype in Metastatic Breast Cancer (2004) (17)
- Expression of a novel lacrimal gland gene lacritin in human breast tissues (2003) (17)
- Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile (2022) (16)
- Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas (2019) (16)
- Clinical patterns and genomic profiling of recurrent ‘ultra-low risk’ endometrial cancer (2020) (16)
- The genomic landscape of metastatic histologic special types of invasive breast cancer (2020) (16)
- PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. (2015) (15)
- Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma (2019) (15)
- The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas (2020) (15)
- Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA (2022) (15)
- Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. (2014) (15)
- Ovarian cancer mutational processes drive site-specific immune evasion (2022) (15)
- Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults (2018) (15)
- Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. (2019) (15)
- Whole‐exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast (2019) (14)
- The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers (2019) (14)
- Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas (2021) (13)
- Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway (2019) (13)
- Diverse BRCA 1 and BRCA 2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (13)
- A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial) (2020) (13)
- TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition (2021) (12)
- Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer (2016) (12)
- The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features (2021) (12)
- The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis. (2020) (11)
- Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes (2020) (11)
- Angiogenic factor AGGF1 acts as a tumor suppressor by modulating p53 post-transcriptional modifications and stability via MDM2. (2020) (11)
- Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies (2021) (11)
- Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications (2017) (11)
- Massively parallel sequencing analysis of benign melanocytic naevi (2019) (10)
- Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes (2020) (10)
- Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors (2020) (10)
- Cancer Causative Mutations Occurring in Early Embryogenesis. (2021) (9)
- Somatic genetic alterations in synchronous and metachronous low‐grade serous tumours and high‐grade carcinomas of the adnexa (2019) (9)
- MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. (2022) (9)
- High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants. (2015) (9)
- Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies. (2019) (8)
- Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast (2017) (8)
- Single-cell genomic variation induced by mutational processes in cancer (2022) (8)
- Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All? (2016) (8)
- Oncogenic properties and signaling basis of the PAX8‐GLIS3 fusion gene (2020) (8)
- The Birth of an Adenoid Cystic Carcinoma (2015) (7)
- The genomic landscape of carcinomas with mucinous differentiation (2021) (7)
- Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (7)
- RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. (2016) (7)
- Genomic characterization of small cell carcinomas of the uterine cervix (2021) (7)
- SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY (2019) (7)
- Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes (2020) (6)
- Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development (2021) (6)
- Genomic analysis of recurrences and high‐grade forms of polymorphous adenocarcinoma (2019) (6)
- TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (6)
- Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing (2022) (6)
- Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes (2021) (6)
- ESR1 and endocrine therapy resistance: more than just mutations. (2018) (6)
- Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. (2021) (6)
- A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor) (2021) (5)
- Whole‐exome analysis of metaplastic breast carcinomas with extensive osseous differentiation (2020) (5)
- The impact of mutational processes on structural genomic plasticity in cancer cells (2021) (5)
- Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? (2017) (5)
- Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma (2021) (5)
- Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? (2017) (5)
- Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (5)
- Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes (2022) (5)
- Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (4)
- Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. (2022) (4)
- Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. (2021) (4)
- Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies (2019) (4)
- Anti-HER2 therapies: when more is more (2012) (4)
- Back to the basis: breast cancer heterogeneity from an etiological perspective. (2014) (4)
- Prognostic signatures in breast cancer: correlation does not imply causation (2012) (4)
- Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (4)
- Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome (2021) (4)
- Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers. (2022) (3)
- Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination (2021) (3)
- ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment (2021) (3)
- Pattern of disease and response to pembrolizumab in recurrent cervical cancer (2021) (3)
- Abstract S4-03: A functional assay for homologous recombination (HR) DNA repair and whole exome sequencing reveal that HR-defective sporadic breast cancers are enriched for genetic alterations in DNA repair genes (2016) (3)
- Molecular classification of endometrial carcinomas: a singleinstitution review (084) (2022) (3)
- Immunogenicity of a public neoantigen derived from mutated PIK3CA (2021) (3)
- The 70-gene prognosis profile predicts early metastases in postmenopausal breast cancer patients. (2009) (3)
- Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites (2020) (3)
- A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
- Abstract 927: Targeted capture next generation sequencing of fresh frozen lobular carcinoma in situ and invasive lobular cancer identifies a common repertoire of mutations (2014) (3)
- Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis (2018) (3)
- Cancer Therapy : Preclinical PI 3 K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (2)
- Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer (2022) (2)
- Abstract S6-06: The genomic landscape of male breast cancers (2015) (2)
- Reply to Rosen (2017) (2)
- PG 2.03 Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa (2015) (2)
- Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: A Multiparameter Test to Rule Them All? (2016) (2)
- Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma (2017) (2)
- Next-Generation Assessment of Human Epithelial Growth Factor Receptor 2 (ERBB2) Amplification Status (2017) (2)
- Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast (2020) (2)
- Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes (2021) (2)
- Abstract S6-06: High-depth massively parallel sequencing reveals heterogeneity between primary tumor and metastatic deposits in de novo metastatic breast cancer patients prior to exposure to systemic therapy (2013) (2)
- Diagnosis and management of an endometrial cancer patient with Cowden syndrome. (2021) (2)
- Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression (2022) (2)
- Epigenetic dysregulation from chromosomal transit in micronuclei (2022) (2)
- PI 3 K pathway activation in high-grade ductal carcinoma in situ — implications for progression to invasive breast carcinoma (2014) (2)
- Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma (2021) (2)
- PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays (2021) (2)
- Discovery of previously undetected micrometastases by mRNA markers in sentinel lymph nodes of breast cancer patients (2004) (2)
- Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification (2012) (1)
- Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. (2022) (1)
- Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (1)
- Lymph node metastases display gene expression profiles of their primary breast carcinomas (2005) (1)
- Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (1)
- Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series (2022) (1)
- Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications (2022) (1)
- Abstract 2989: Intra-tumor heterogeneity and clonal changes in the progression of DCIS to invasiveness: Combined tumor bulk and single cell analysis (2015) (1)
- Triple-Negative and Basal-like Carcinoma (2012) (1)
- Abstract P4-05-08: Genomic landscape of breast cancer occurring in elderly individuals (2020) (1)
- Genomic Applications in Gynecologic Malignancies (2018) (1)
- Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. (2022) (1)
- Prognostic signatures in breast cancer: correlation does not imply causation (2012) (1)
- Circulating cell-free DNA in patients with newly diagnosed and recurrent cervical cancer (2020) (1)
- Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer (2022) (1)
- Homologous recombination DNA repair defects in copy-number high serous-like endometrial cancers (2019) (1)
- EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy. (2022) (1)
- Abstract P6-03-10: Genomic and transcriptomic heterogeneity in metaplastic breast carcinomas (2016) (1)
- Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old (2019) (1)
- Breast cancer intra-tumor heterogeneity (2014) (1)
- Human Cancer Biology PI 3 K Pathway Activation in High-Grade Ductal Carcinoma In Situ — Implications for Progression to Invasive Breast Carcinoma (2014) (1)
- Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. (2020) (1)
- Abstract P3-06-08: Mucinous and neuroendocrine breast cancers: A spectrum of genetically-related lesions distinct from common forms of estrogen receptor-positive breast cancers (2019) (1)
- Genomic Applications in Breast Carcinoma (2018) (1)
- Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors (2015) (1)
- Abstract S2-02: The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers (2016) (1)
- Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma (2020) (1)
- Combining two antibodies to define E‐cadherin loss of expression in non‐lobular breast carcinomas: when less is more (2013) (1)
- Abstract 2553: Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes (2022) (1)
- TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (1)
- Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. (2022) (1)
- Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (1)
- Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification. (2022) (1)
- Landscape of chromatin remodeling gene alterations in endometrial carcinoma. (2023) (1)
- Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix (2022) (1)
- Abstract A2-02: SF3B1 mutations constitute a novel therapeutic target in breast cancer (2015) (1)
- Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (1)
- Blocking metastatic behavior of MUC16/CA-125-expressing cancer by targeting galectin-3 (2019) (1)
- Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
- Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients with Primary and Metastatic Breast Cancer (2018) (1)
- Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies (2015) (1)
- O015/#502 Molecular stratification of ovarian clear cell carcinoma predicts clinical outcomes (2022) (1)
- The importance of gene-centring microarray data – Authors' reply (2010) (1)
- Granular cell tumor of thyroid: a case series with molecular characterization highlighting unique pitfalls (2022) (1)
- Germline risk assessment and genetic counseling in ovarian cancer patients of diverse self-reported race/ethnicity and ancestry (388) (2022) (1)
- Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (1)
- Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers (2022) (1)
- Abstract P2-05-03: Novel driver genetic alterations in MYB-NFIB-negative breast adenoid cystic carcinomas (2018) (0)
- Abstract PD14-03: Genetic and epigenetic basis of invasive lobular carcinomas lacking CDH1-alterations (2022) (0)
- Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers. (2015) (0)
- The genomic profiling of penile carcinoma: DNA copy number aberrations and validation of candidate driver genes (2017) (0)
- CDKN2A loss-of-function genetic alterations in uterine sarcoma: prognostic implications and potential therapeutic target (2021) (0)
- 431 Distant metastatic spread and clonal evolution of high-grade endometrial cancers (2020) (0)
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (0)
- Recent advances in breast cancer (2016) (0)
- 575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer (2014) (0)
- Prognosis of isolated tumor cells and the utility of molecular classification in early stage endometrioid endometrial cancer (243) (2022) (0)
- Next-Generation Assessment of ERBB2 (HumanEpidermal Growth Factor Receptor 2) Amplification Status (2016) (0)
- Male breast cancer : genomic profiling 1 The Genomic Landscape of Male Breast Cancers (2016) (0)
- Abstract 138: Solid papillary carcinoma with reverse polarization are driven by IDH2 and PI3K pathway mutations (2016) (0)
- Abstract P4-05-01: Massively parallel sequencing analysis of microsatellite instability in breast cancer (2020) (0)
- Abstract P4-05-07: Whole-exome and RNA-sequencing analyses of acinic cell carcinomas of the breast (2020) (0)
- EP005/#572 Exploiting SMARCA2 dependency for targeted therapy in SMARCA4-deficient ovarian cancers (2022) (0)
- Author ' s response to reviews Title : SDHA Loss of Function Mutations in a Subset of Young Adult Wild-type Gastrointestinal (2012) (0)
- Abstract 3889: Genetic heterogeneity and distinct driver mutations in synchronous primary and metastatic breast cancers from therapy-naïve patients (2015) (0)
- EPV005/#536 Molecular analysis of primary endometrial cancer and matched lung metastases (2021) (0)
- O017/#479 Germline pathogenic variants in DNA repair genes and endometrial cancer risk (2022) (0)
- Molecular markers of breast cancer metastasis (2005) (0)
- EP111/#458 Sectioning and extensively examining the fimbriated end of fallopian tubes for endometrial cancer (2022) (0)
- 229 Genetic heterogeneity of ovarian sex cord-stromal tumors (2019) (0)
- Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas (2021) (0)
- Abstract 1544: The clinical behavior of endometrioid and serous endometrial carcinomas is governed by distinct biological processes (2014) (0)
- The amount of circulating cell-free DNA present in plasma of endometrial cancer patients is associated with surgical stage, histology and MRI-defined tumor volume (2019) (0)
- Abstract 91: The mutational landscape of mucinous carcinomas of the breast (2016) (0)
- Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (0)
- Abstract P2-06-04: Pathognomonic long molecule footprints of backup repair pathways in homologous recombination deficient cancers (2022) (0)
- Abstract P2-03-08: Mutational landscape of metaplastic breast carcinomas (2015) (0)
- Abstract P6-07-04: Distinct repertoires of somatic mutations affecting driver genes in mucinous and neuroendocrine carcinomas of the breast (2016) (0)
- Abstract P4-02-01: High-depth sequencing of circulating tumor DNA to interrogate the genetics of residual micro-metastatic disease prior to relapse in early breast cancer (2015) (0)
- Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- Genomic analysis of high-grade serous ovarian cancer in young and older women (2020) (0)
- Association of CD8+ T cell gene expression signatures with outcomes in the distinct molecular subtypes of endometrial cancer (2020) (0)
- Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related (2019) (0)
- Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes. (2020) (0)
- Genomic analysis of serous tubal intraepithelial carcinoma-like lesions and concurrent endometrial serous carcinoma: Related entities? (2020) (0)
- Systemic and intratumoral stress responses to primary debulking surgery in patients with epithelial ovarian cancer (2020) (0)
- Abstract 4735: Single-cell sequencing from formalin-fixed paraffin-embedded breast cancers: a powerful tool to address intratumor genetic heterogeneity (2015) (0)
- Abstract P2-01-02: Whole exome sequencing analysis of the progression from ductal carcinomain situto invasive ductal carcinoma (2019) (0)
- Endometrial cancers in or germline mutations carriers (2019) (0)
- Abstract P2-01-02: Capturing intra-tumor genetic heterogeneity in cell-free plasma DNA from patients with oligometastatic breast cancer (2016) (0)
- Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer (2022) (0)
- Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type (2020) (0)
- Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (0)
- Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (0)
- CLONALITY ANALYSIS OF SYNCHRONOUS ENDOMETRIAL AND OVARIAN CARCINOMAS IN PATIENTS WITH LYNCH SYNDROME (2019) (0)
- Treatment with the PARP inhibitor olaparib in a patient with PTEN-deficient endometrial cancer (2011) (0)
- Abstract 4817: Microsatellite instability status in endometrioid endometrial carcinomas is associated with distinct types and patterns of PI3K pathway mutations (2015) (0)
- How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma (2019) (0)
- Abstract 4835: Genetic determinants of mTOR inhibitor response in breast and endometrial cancer (2012) (0)
- EP299/#232 Genomic instability as a determinant of immune escape in ovarian cancer (2022) (0)
- Abstract P2-05-08: Mucinous breast carcinomas: A genomically distinct subtype of estrogen receptor-positive invasive breast cancers (2018) (0)
- The genomic landscape of metastatic histologic special types of invasive breast cancer (2020) (0)
- Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (0)
- Molecular profiling of endometrioid ovarian carcinomas (2019) (0)
- ESR1 HOTSPOT MUTATIONS IN ENDOMETRIAL STROMAL SACROMAS MAY CONFER HORMONAL RESISTANCE (2019) (0)
- Abstract 3768: Epigenetic dysregulation from chromosomal transit in micronuclei (2022) (0)
- Landscape of somatic genetic alterations in endometrioid endometrial cancers with germline and somatic PTEN mutations (2018) (0)
- Abstract 2949: Enabling single cell analysis of copy number variation in breast cancer (2022) (0)
- Risk stratification of stage I grade 3 endometrioid endometrial carcinoma (083) (2022) (0)
- Classification of prospectively collected endometrial cancers into prognostically relevant subgroups using massively parallel sequencing and immunohistochemistry (2018) (0)
- Abstract P2-05-01: Single cell sequencing analysis of formalin-fixed paraffin-embedded ductal carcinomas in situ and invasive breast cancers reveals clonal selection in the progression from in situ to invasive disease (2016) (0)
- Abstract LB089: Effective in vivo treatment of endometrial tumor models with coexistent mutant PI3K and PTEN inactivation with a selective bi-steric mTORC1 kinase inhibitor (2022) (0)
- Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development (2021) (0)
- Abstract P1-05-03: The genomic landscape of breast metaplastic carcinoma (2017) (0)
- Abstract PD4-5: Longitudinal massively parallel sequencing analysis of circulating cell-free tumor DNA: A feasibility study (2013) (0)
- Abstract LB-335: Loss of function of the BRCA1-PALB2-BRCA2 axis accelerates p53-associated tumorigenesis (2020) (0)
- KIT genetic alterations in breast cancer (2022) (0)
- Mutation detection in cell-free DNA using ultra-high depth sequencing in prospectively collected newly diagnosed endometrial cancer patients (2020) (0)
- Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (0)
- Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ (2016) (0)
- Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors (2022) (0)
- Comparisons of ECCs with endometrial carcinomas from the TCGA dataset (2017) (0)
- Abstract P4-04-01: The landscape of somatic genetic alterations in breast cancers fromCHEK2germline mutation carriers (2019) (0)
- Abstract PD8-06: The genomic landscape of metastatic special histologic types of breast cancer (2020) (0)
- Abstract 4472: PI3K pathway dependencies in endometrioid endometrial cancer. (2013) (0)
- Abstract P1-05-04: Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations (2017) (0)
- TERT Hotspot Promoter Mutations and TERT Gene Amplification in Phyllodes Tumors of the Breast (2016) (0)
- Abstract 130: Distinct mutational drivers and evolutionary pathways in stage IA non-myoinvasive endometrioid endometrial cancer (2023) (0)
- Abstract P4-05-11: Methylation profiling of mucinous breast cancer (2020) (0)
- Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer (2022) (0)
- Genetic Discoveries and Pathologic Variations in Ovarian Cancer Moderators: Charles Landen, MD, and Barbara Norquist, MD May 22, 3:30 p.m. CST Histopathological characterization of the tubal fimbria reveals a subgroup of BRCA1 mutation carriers with tumor- promoting gene-set enrichment (2020) (0)
- Abstract 2470: Compromised BRCA1-PALB2 interaction is associated with breast cancer risk (2017) (0)
- Gene expression profiles of primary breast tumors maintained in lymph node- and distant metastases (2004) (0)
- Abstract P3-06-07: Recurrent but not pathognomonic fusion genes in mucinous carcinomas of the breast (2019) (0)
- Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation (2022) (0)
- Exploring Collagen Parameters in Pure Special Types of Invasive Breast Cancer (2019) (0)
- Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models (2023) (0)
- NR4A3 Expression is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift. (2023) (0)
- Uterine carcinosarcomas and metaplastic breast carcinomas: Genetically related cancers? (2020) (0)
- Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer (2020) (0)
- Unraveling the microenvironmental influences on the normal mammary gland and induction and progression of breast cancer (2009) (0)
- Intrauterine lavage as a novel method of detecting somatic mutations present in high-grade serous cancer of the ovary, fallopian tube or peritoneum (2020) (0)
- Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice (2020) (0)
- Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (0)
- Abstract P4-04-08: Genomic and transcriptomic characterization of papillary carcinomas of the breast (2013) (0)
- Gene set enrichment clustering and the tumor microenvironment in primary high-grade serous ovarian cancer (HGSOC) (2018) (0)
- Abstract PD8-09: Bi-allelic alterations in homologous recombination (HR) DNA repair-related genes as the basis for HR defects in human cancers: A pan-cancer genomics and functional analysis (2018) (0)
- Clinicopathologic characteristics of endometrial carcinoma metastatic to the ovary compared to endometrial carcinoma with synchronous ovarian carcinoma. (2017) (0)
- The Genomic Landscape of PALB2-Associated Breast Cancers (2017) (0)
- Abstract 2971: Whole exome sequencing reveals heterogeneity within lobular carcinoma in situ (LCIS) and clonal selection in the progression to malignant lesions (2015) (0)
- 116 ESR1 hotspot mutations in endometrial stromal sacromas may confer hormonal resistance (2019) (0)
- The importance of gene-centring microarray data Reply (2010) (0)
- Abstract PD1-4: Somatic leukemogenic mutations associated with infiltrating white blood cells in breast cancer patients (2015) (0)
- Abstract 4029: The impact of multiple drug resistance mechanisms on microarray predictive gene signature performance. (2013) (0)
- 234 Clonality analysis of synchronous endometrial and ovarian carcinomas in patients with lynch syndrome (2019) (0)
- Abstract PD1-15: The landscape of somatic genetic alterations in breast cancers fromATMgermline mutation carriers (2018) (0)
- 12 Genetic analysis of primary and recurrent adult granulosa cell tumors of the ovary (2019) (0)
- Abstract B007: Endogenous retrotransposable elements induction in SMARCA4-deficient ovarian cancer is associated with immunomodulatory changes in the tumor microenvironment (2022) (0)
- UvA-DARE ( Digital Academic Repository ) Molecular markers of breast cancer metastasis (2009) (0)
- Abstract P2-03-09: Benchmarking mutation function prediction algorithms using validated cancer driver and passenger mutations (2015) (0)
- Molecular and pathologic data can guide selection of endometrioid endometrial cancer patients for ovarian preservation (239) (2022) (0)
- Marked inter- and intra-patient heterogeneity of T cell infiltrates in primary high-grade serous ovarian cancer (2017) (0)
- RESULTS Genomic Features of Advanced , Post-Treatment Breast Cancer (2019) (0)
- Genetic heterogeneity of sertoli-leydig and juvenile-type granulosa cell tumors (2020) (0)
- Abstract 3379: Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven byHRAShotspot mutations (2017) (0)
- Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models (2022) (0)
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (0)
- O015/#436 Comprehensive genomic profiling of low-grade serous cancers and associated clinical outcomes (2021) (0)
- Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination (2021) (0)
- Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways (2017) (0)
- Hyperthermic intraperitoneal chemoperfusion (HIPEC) with carboplatin and its effect on the transcriptome of ovarian cancer and normal tissues (2020) (0)
- Germline drivers of gynecologic carcinosarcomas (2023) (0)
- Abstract P2-03-01: Mutational landscape of breast cancers from PALB2 germline mutation carriers (2016) (0)
- Abstract S4-04: Lobular carcinoma in situ displays intra-lesion genetic heterogeneity and its progression to invasive disease involves clonal selection and variations in mutational processes (2016) (0)
- Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. (2022) (0)
- Identification of endometrial cancer mutations in pelvic washings using massively parallel sequencing: A pilot study (2020) (0)
- Compositional and architectural characterization of high-grade serous ovarian carcinomas using single cell technologies and multiplex microscopy (2020) (0)
- Whole-exome sequencing and clonal evolution of brain metastases in low-grade early-stage endometroid endometrial adenocarcinoma (2020) (0)
- Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer (2019) (0)
- Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (0)
- Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1‐CYP2E1 fusions (2022) (0)
- Endometrial cancers in BRCA1 or BRCA2 germline mutations carriers (2019) (0)
- Cervical Pleuropulmonary Blastoma-like Tumor Associated With DICER1 and TP53 Mutations. (2022) (0)
- The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer. (2018) (0)
- 9 Genomic profiling of recurrent “ultra-low risk” endometrial cancer (2019) (0)
- Abstract 1692: Single-cell DNA sequencing from frozen endometrial tumors to address clonal evolution of somatic mutations (2022) (0)
- Abstract 5076: Integrative genomic and transcriptomic analysis of metaplastic carcinomas of the breast (2012) (0)
- Ovarian RASoma With Mesonephric-like Adenocarcinoma and Mixed Mullerian Components: A Case Report With Molecular Analysis Demonstrating Multidirectional Mullerian Differentiation. (2023) (0)
- High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer. (2022) (0)
- Abstract P6-03-05: Dual HER2 blockade of an activating driverHER3mutation: A proof of principle study in a metastatic breast cancer patient (2015) (0)
- Overall gene-expression profile of triple-negative tumors associated with disease outcome (2011) (0)
- Abstract 3885: Mutational landscape and copy number alterations of mucinous breast carcinoma (2015) (0)
- Mutational signature analysis of primary and metastatic endometrial cancer reveals associations with molecular subtypes and shifts during tumor progression (2019) (0)
- OP-JNCI190159 107..110 (2020) (0)
- Abstract P6-06-02: GermlineCDH1mutations in lobular carcinomain situ (2016) (0)
- Abstract 4258: Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations (2014) (0)
- Title : Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by enhancing collagen deposition (2013) (0)
- Abstract P4-04-05: Molecular subtyping reveals the heterogeneity of metaplastic breast cancers (2013) (0)
- Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer. (2022) (0)
- Abstract P6-09-01: RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects (2020) (0)
- Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer (2022) (0)
- Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation. (2022) (0)
- Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. (2023) (0)
- Comprehensive Analysis of Germline Drivers in Endometrial Cancer. (2023) (0)
- GENETIC HETEROGENEITY OF OVARIAN SEX CORD-STROMAL TUMORS (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Britta Weigelt?
Britta Weigelt is affiliated with the following schools:
